[Antihypertensive effect of fosinopril in mild hypertension]. 1996

M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
Serviço de Medicina 2, Hospital de S. Joäo, Porto.

The aim of this double-blind randomized placebo-controlled study was to evaluate the antihypertensive and safety of fosinopril in mild essential hypertension. After a 2-week placebo period, patients received either placebo or fosinopril 20 mg, once daily. Thirty-four patients finished the study (18 patients in the placebo group and 16 patients in the fosinopril group). Systolic blood pressure decreased from 160.1 +/- 22.1 mmHg to 156.0 +/- 24.2 in the placebo group (NS) and from 151.8 +/- 14.0 mmHg to 141.5 +/- 14.5 in the fosinopril group (p < 0.005); diastolic blood pressure decreased from 100.1 +/- 2.4 mmHg to 94.3 +/- 7.4 mmHg in the placebo group (p < 0.005) and from 100.8 +/- 4.8 mmHg to 88.1 +/- 9.0 mmHg in the fosinopril group (p < 0.001). Mean decrease in diastolic blood pressure was 5.7 mmHg in the placebo group and 12.6 mmHg in the fosinopril group (p < 0.05). A statistically significant difference was seen between the percentage of controlled patients in the two groups: 16.6% in the placebo group vs 56.2% in the fosinopril group (p < 0.05). No statistically significant difference in biochemical parameters was seen between the two groups. Tolerance was good and no patients were withdrawn from the study for adverse events.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
May 1994, Arquivos brasileiros de cardiologia,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
September 1973, JAMA,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
January 1981, Acta medica Scandinavica. Supplementum,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
December 1991, Journal of internal medicine,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
January 1990, Clinical therapeutics,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
January 2009, Journal of dietary supplements,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
January 1989, Indian heart journal,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
August 2008, Fundamental & clinical pharmacology,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
January 2006, Blood pressure,
M Pizarro, and M J Lima, and J Domingues, and A C Gouveia, and A Monteiro, and M Carrageta, and A F de Freitas
January 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Copied contents to your clipboard!